Literature DB >> 21479482

Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia.

Niklas Mattsson1, Ulla Rüetschi, Yolande A L Pijnenburg, Marinus A Blankenstein, Vladimir N Podust, Susann Li, Inger Fagerberg, Lars Rosengren, Kaj Blennow, Henrik Zetterberg.   

Abstract

Frontotemporal dementia (FTD) is a heterogeneous disease with substantial interpersonal variance in aggressiveness. Novel biomarkers for rapidly progressive FTD could improve diagnosis and provide clues regarding its pathogenesis. In this study, surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry (MS) was used to analyze peptide profiles in cerebrospinal fluid (CSF) from 24 FTD patients. Thirteen patients had rapidly progressive FTD with distinct pathology in a brain MRI after less than 3 years of disease duration. Eleven patients had slowly progressive FTD with a normal brain MRI, but had abnormal findings in SPECT/PET after more than 5 years of disease duration. The axonal damage marker CSF neurofilament light-chain (NF-L) was measured in all subjects to evaluate the amount of axonal degeneration. A CSF NF-L level of 150 ng/l was used as a cut-off point for high NF-L expression. SELDI-TOF analysis of peptides in the range of 2000-20000 m/z revealed one peak with m/z of 6378 that was expressed at a significantly different level (p<0.01) when rapidly versus slowly progressive cases of FTD were compared. Eleven peaks were expressed at different levels when high versus low CSF NF-L were compared. Using chromatographic purification followed by tandem mass spectrometric analysis, five of these peaks were identified as follows: C-terminal fragment of neuroendocrine protein 7B2 (3512.84 Da), C-terminal fragment of osteopontin (7658.19 Da) as well as its mono- and diphosphorylated forms (7738.16 Da and 7818.13 Da, respectively) and pancreatic ribonuclease (14566.33 Da). The peak intensity of pancreatic ribonuclease was higher in patients with low NF-L expression, while the other peptides had a lower peak intensity in this group. Altered levels of these peptides have also been described in other neurodegenerative diseases. Taken together, these data suggest that differentially-expressed peptides are general markers of axonal degeneration. Further studies are needed to verify their prognostic value in FTD.

Entities:  

Year:  2008        PMID: 21479482     DOI: 10.3892/mmr_00000025

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  18 in total

Review 1.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

2.  CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis.

Authors:  Daniela Rossi; Paolo Volanti; Liliana Brambilla; Tiziana Colletti; Rossella Spataro; Vincenzo La Bella
Journal:  J Neurol       Date:  2018-01-10       Impact factor: 4.849

Review 3.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

4.  OSTEOPONTIN: A KEY LINK BETWEEN IMMUNITY, INFLAMMATION AND THE CENTRAL NERVOUS SYSTEM.

Authors:  Amanda Brown
Journal:  Transl Neurosci       Date:  2012-02-01       Impact factor: 1.757

Review 5.  Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders.

Authors:  Zahra Alirezaei; Mohammad Hossein Pourhanifeh; Sarina Borran; Majid Nejati; Hamed Mirzaei; Michael R Hamblin
Journal:  Mol Neurobiol       Date:  2019-08-05       Impact factor: 5.590

6.  Protein markers for the differential diagnosis of vascular dementia and Alzheimer's disease.

Authors:  A H Simonsen; N-O Hagnelius; G Waldemar; T K Nilsson; J McGuire
Journal:  Int J Proteomics       Date:  2012-06-04

7.  Cortical neurons are a prominent source of the proinflammatory cytokine osteopontin in HIV-associated neurocognitive disorders.

Authors:  Katie Silva; Calixto Hope-Lucas; Tyesha White; Tai-Kyung Hairston; Tatenda Rameau; Amanda Brown
Journal:  J Neurovirol       Date:  2015-01-31       Impact factor: 2.643

8.  Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics.

Authors:  Charlotte E Teunissen; Naura Elias; Marleen J A Koel-Simmelink; Sisi Durieux-Lu; Arjan Malekzadeh; Thang V Pham; Sander R Piersma; Tommaso Beccari; Lieke H H Meeter; Elise G P Dopper; John C van Swieten; Connie R Jimenez; Yolande A L Pijnenburg
Journal:  Alzheimers Dement (Amst)       Date:  2016-01-19

9.  Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease.

Authors:  David J Irwin; John Q Trojanowski; Murray Grossman
Journal:  Front Aging Neurosci       Date:  2013-02-21       Impact factor: 5.750

10.  CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease.

Authors:  William T Hu; Kelly D Watts; Prashant Tailor; Trung P Nguyen; Jennifer C Howell; Raven C Lee; Nicholas T Seyfried; Marla Gearing; Chadwick M Hales; Allan I Levey; James J Lah; Eva K Lee
Journal:  Acta Neuropathol Commun       Date:  2016-02-17       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.